7 results match your criteria Pulmonary Fibrosis Interstitial Nonidiopathic

  • Page 1 of 1

Diagnosis and Management of Fibrotic Interstitial Lung Diseases.

Clin Chest Med 2021 Jun;42(2):321-335

Department of Medicine and Surgery, University of Milan Bicocca; Pneumology Unit, Ospedale "S. Gerardo", ASST Monza, Monza, Italy.

Nonidiopathic pulmonary fibrosis (non-IPF) progressive fibrotic interstitial lung diseases (PF-ILDs) are a heterogeneous group of ILDs, often challenging to diagnose, although an accurate diagnosis has significant implications for both treatment and prognosis. A subgroup of these patients experiences progressive deterioration in lung function, physical performance, and quality of life after conventional therapy. Risk factors for ILD progression include older age, lower baseline pulmonary function, and a usual interstitial pneumonia pattern. Read More

View Article and Full-Text PDF

Acute exacerbation in interstitial lung disease.

Ann Thorac Med 2021 Apr-Jun;16(2):178-187. Epub 2021 Apr 17.

Department of Radiology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Background: Information regarding acute exacerbation (AE) in patients with interstitial lung disease (ILD) is limited.

Objectives: The objective of the study was to elucidate the clinical features and outcome of AE among ILD patients.

Methods: We retrospectively analyzed the data of 667 consecutive ILD (nonidiopathic pulmonary fibrosis [IPF] ILD, = 463; IPF, = 204) patients. Read More

View Article and Full-Text PDF

Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP).

Lung India 2020 Jul-Aug;37(4):359-378

Department of Medicine, PGIMS, Rohtak, Haryana, India.

Background: Interstitial lung disease (ILD) is a complex and heterogeneous group of acute and chronic lung diseases of several known and unknown causes. While clinical practice guidelines (CPG) for idiopathic pulmonary fibrosis (IPF) have been recently updated, CPG for ILD other than IPF are needed.

Methods: A working group of multidisciplinary clinicians familiar with clinical management of ILD (pulmonologists, radiologist, pathologist, and rheumatologist) and three epidemiologists selected by the leaderships of Indian Chest Society and National College of Chest Physicians, India, posed questions to address the clinically relevant situation. Read More

View Article and Full-Text PDF

Clinical implications of telomere dysfunction in lung fibrosis.

Curr Opin Pulm Med 2018 09;24(5):440-444

Service de Pneumologie, Centre constitutif du centre de référence, des Maladies Pulmonaires Rares, DHU FIRE, Hôpital Bichat, APHP, INSERM, Unité 1152, LabEx Inflamex, Paris, France.

Purpose Of Review: Telomere attrition has been proposed as one of the aging hallmarks in pulmonary fibrosis. Telomere shortening and telomerase gene mutations have been widely evaluated in recent years. Reduced telomere length may be identified in a quarter of patients with sporadic idiopathic pulmonary fibrosis (IPF) and half of those cases with family aggregation. Read More

View Article and Full-Text PDF
September 2018

Unclassifiable interstitial lung disease: from phenotyping to possible treatments.

Curr Opin Pulm Med 2018 09;24(5):461-468

Department of Medicine, University of British Columbia.

Purpose Of Review: Accurate diagnosis of interstitial lung diseases (ILDs) can be challenging, and a substantial percentage of ILD patients remain unclassifiable even after thorough assessment by an experienced multidisciplinary team. In this review, we summarize the recent literature on the definition, prevalence, diagnosis, treatment, and prognosis of unclassifiable ILD, and also discuss important current issues and provide future perspectives on the classification of ILD.

Recent Findings: Approximately 12% of patients with ILD are considered unclassifiable, with large variability across previous studies that is in part secondary to inconsistent definitions of unclassifiable ILD and other ILD subtypes. Read More

View Article and Full-Text PDF
September 2018

Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?).

Curr Opin Pulm Med 2017 09;23(5):418-425

aCenter for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Critical Care Medicine, Thoraxklinik, University of Heidelberg, Heidelberg bMember of the German Center for Lung Research cDepartment of Internal Medicine V, Comprehensive Pneumology Center, Asklepios Fachkliniken, University of Munich, Munich, Bavaria, Germany.

Purpose Of Review: Therapeutic advances in the management of idiopathic pulmonary fibrosis (IPF) has led to improved outcomes with the use of the antifibrotic agents pirfenidone and nintedanib, with a number of randomized studies demonstrating benefits in slowing disease progression in IPF. However, treatment of other fibrosing interstitial lung diseases (ILD) remains challenging.

Recent Findings: Observational and uncontrolled studies investigating pirfenidone and nintedanib in non-IPF ILDs suggest potential benefits, although the data is weak. Read More

View Article and Full-Text PDF
September 2017
  • Page 1 of 1